je.st
news
Tag: rate
New KEYTRUDA (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients
2016-10-08 08:15:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Results from Interim Analysis of Phase 2 KEYNOTE-052 Study to be Presented at ESMO 2016 Congress and Highlighted in ESMO Press Program First Presentation of Data Investigating KEYTRUDA in the Front Line Treatment of Bladder Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive findings from the phase 2 KEYNOTE-052 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in previously untreated patients with unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
rate
response
Pebble 2 + Heart Rate
2016-10-05 23:02:54| PC Magazine: New Product Reviews
The Pebble 2 + Heart Rate is a very good smartwatch, but its fitness-tracking features could stand to be improved.
Rate Conventions
2016-10-05 21:44:17| PortlandOnline
PDF Document, 58kbCategory: October 4, 2016 Materials
Tags: rate
conventions
Pebble 2 + Heart Rate
2016-10-05 21:03:14| PC Magazine: New Product Reviews
The Pebble 2 + Heart Rate is a very good smartwatch, but its fitness-tracking features could stand to be improved.
Collections and Foreclosure Process Redemption Interest Rate and Redemption Penalty Rate
2016-10-05 01:23:58| PortlandOnline
BCP-FIN-12.09
Tags: rate
process
interest
collections
Sites : [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] next »